ESR1 PvuII Polymorphism: from Risk Factor to Prognostic and Predictive Factor of the Success of Primary Systemic Therapy in Advanced Breast Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2021 Dec 21

PMID 34930150

Citations 2

Authors

Ramadhan Karsono

Samuel J Haryono

Bambang Karsono

Wirsma Arif Harahap

Yulia Pratiwi

Teguh Aryandono

Affiliations

Soon will be listed here.

Abstract

Background: The ESR1 gene encodes Estrogen Receptor alpha (ERα), which plays a role in the tumourigenesis of breast cancer. A single nucleotide polymorphism (SNP) in intron 1 of this gene called ESR1 PvuII (rs2234693) has been reported to increase the risk of breast cancer. This study aimed to investigate the ESR1 PvuII polymorphism as a prognostic and predictive factor guiding the choice of therapy for advanced breast cancer.

Methods: This retrospective study was conducted in 104 advanced breast cancer patients at Dharmais Cancer Hospital from 2011 to 2018. The ESR1 PvuII polymorphism was analysed by Sanger sequencing of DNA from primary breast tumour samples.

Results: The percentages of patients with ESR1 PvuII genotypes TT, TC, and CC were 42.3, 39.4, and 18.3%, respectively. Looking at prognosis, patients with ESR1 PvuII TC + CC had shorter overall survival than those with the TT genotype [HR = 1.79; 95% CI 1.05-3.04; p = 0.032]. As a predictive marker, TC + CC was associated with shorter survival (p = 0.041), but TC + CC patients on primary hormonal therapy had a median overall survival longer than TC + CC patients on primary chemotherapy (1072 vs 599 days).

Conclusion: The ESR1 PvuII TC + CC genotypes confer poor prognosis in advanced breast cancer, but these genotypes could be regarded as a good predictor of the therapeutic effect of hormonal treatment.

Citing Articles

Prediction of medication-related osteonecrosis of the jaws using machine learning methods from polymorphisms and clinical information.

Choi S, Kim J, Oh S, Cheon S, Yee J, Kim S Front Med (Lausanne). 2023; 10:1140620.

PMID: 37415765 PMC: 10321771. DOI: 10.3389/fmed.2023.1140620.

Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysis.

Fang D, Li Y, Li Y, Chen Y, Huang Q, Luo Z Gland Surg. 2022; 11(6):1026-1036.

PMID: 35800743 PMC: 9253195. DOI: 10.21037/gs-22-234.

References

Markiewicz A, Welnicka-Jaskiewicz M, Skokowski J, Jaskiewicz J, Szade J, Jassem J . Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients. PLoS One. 2013; 8(8):e72219. PMC: 3738574. DOI: 10.1371/journal.pone.0072219. View

Kuo S, Yang S, You S, Lien H, Lin C, Lin P . Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer. Oncotarget. 2017; 8(13):20925-20938. PMC: 5400556. DOI: 10.18632/oncotarget.14995. View

Billam M, Witt A, Davidson N . The silent estrogen receptor--can we make it speak?. Cancer Biol Ther. 2009; 8(6):485-96. PMC: 3901993. DOI: 10.4161/cbt.8.6.7582. View

Wilcken N, Hornbuckle J, Ghersi D . Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev. 2003; (2):CD002747. PMC: 8094405. DOI: 10.1002/14651858.CD002747. View

Semiglazov V, Semiglazov V, Dashyan G, Ziltsova E, Ivanov V, Bozhok A . Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007; 110(2):244-54. DOI: 10.1002/cncr.22789. View

Hu X, Jiang L, Tang C, Ju Y, Jiu L, Wei Y . Association of three single nucleotide polymorphisms of ESR1with breast cancer susceptibility: a meta-analysis. J Biomed Res. 2017; 31(3):213-225. PMC: 5460609. DOI: 10.7555/JBR.31.20160087. View

Niu J, Andres G, Kramer K, Kundranda M, Alvarez R, Klimant E . Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients. Onco Targets Ther. 2015; 8:3323-8. PMC: 4648593. DOI: 10.2147/OTT.S92443. View

Goldhirsch A, Wood W, Coates A, Gelber R, Thurlimann B, Senn H . Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22(8):1736-47. PMC: 3144634. DOI: 10.1093/annonc/mdr304. View

Palmieri C, Cleator S, Kilburn L, Kim S, Ahn S, Beresford M . NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. Breast Cancer Res Treat. 2014; 148(3):581-90. DOI: 10.1007/s10549-014-3183-4. View

10.

Bahreini A, Levine K, Santana-Santos L, Benos P, Wang P, Andersen C . Non-coding single nucleotide variants affecting estrogen receptor binding and activity. Genome Med. 2016; 8(1):128. PMC: 5154163. DOI: 10.1186/s13073-016-0382-0. View

11.

Gown A . Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008; 21 Suppl 2:S8-S15. DOI: 10.1038/modpathol.2008.34. View

12.

Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D . Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol. 2016; 2(10):1310-1315. PMC: 5063698. DOI: 10.1001/jamaoncol.2016.1279. View

13.

Akhsan A, Aryandono T . Prognostic factors of locally advanced breast cancer patients receiving neoadjuvant and adjuvant chemotherapy. Asian Pac J Cancer Prev. 2010; 11(3):759-61. View

14.

Robinson D, Wu Y, Vats P, Su F, Lonigro R, Cao X . Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013; 45(12):1446-51. PMC: 4009946. DOI: 10.1038/ng.2823. View

15.

Widodo I, Dwianingsih E, Triningsih E, Utoro T, Soeripto . Clinicopathological features of indonesian breast cancers with different molecular subtypes. Asian Pac J Cancer Prev. 2014; 15(15):6109-13. DOI: 10.7314/apjcp.2014.15.15.6109. View

16.

Lu H, Chen D, Hu L, Zhou L, Xu H, Bai Y . Estrogen receptor alpha gene polymorphisms and breast cancer risk: a case-control study with meta-analysis combined. Asian Pac J Cancer Prev. 2014; 14(11):6743-9. DOI: 10.7314/apjcp.2013.14.11.6743. View

17.

Alba E, Calvo L, Albanell J, De la Haba J, Arcusa Lanza A, Chacon J . Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012; 23(12):3069-3074. DOI: 10.1093/annonc/mds132. View

18.

Spring L, Gupta A, Reynolds K, Gadd M, Ellisen L, Isakoff S . Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016; 2(11):1477-1486. PMC: 5738656. DOI: 10.1001/jamaoncol.2016.1897. View

19.

Carson E, Dear R . Advanced breast cancer: An update to systemic therapy. Aust J Gen Pract. 2019; 48(5):278-283. DOI: 10.31128/AJGP-10-18-4729. View

20.

Hertz D, Henry N, Kidwell K, Thomas D, Goddard A, Azzouz F . ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors. Physiol Genomics. 2016; 48(9):688-98. PMC: 5111879. DOI: 10.1152/physiolgenomics.00065.2016. View